The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients … (NCT06778330) | Clinical Trial Compass
CompletedNot Applicable
The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension
Egypt100 participantsStarted 2025-01-20
Plain-language summary
This study aims to determine the efficacy of sildenafil (improve PAH) as an add-on therapy to dapagliflozin in the treatment of heart failure patients with secondary pulmonary arterial hypertension and compare the result with monotherapy dapagliflozin
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
patients with established heart failure with secondary pulmonary hypertension seen by a primary care provider to diagnose a heart disease, the patient's symptoms which may experience:
* Dizziness or fainting
* Heart palpitations, which may feel like your heart fluttering or skipping beats
* Shortness of breath
Exclusion Criteria:
* Patients with a history of severe allergic reactions or hypersensitivity to sildenafil, dapagliflozin, or related medications.
* Individuals with contraindications to the use of sildenafil or dapagliflozin.
* Patients with pulmonary arterial hypertension (PAH) due to conditions other than heart failure (e.g., idiopathic PAH).
* severe hepatic impairment
* aged less than 18 years.
* valvular heart disease .
* Patients with a known or suspected history of non-compliance with medical treatment or inability to adhere to study procedures.
* life expectancy of less than 6 months .
* Pregnant or breastfeeding women